Ads
related to: chronic fatigue ritalin treatment plan printable
Search results
Results From The WOW.Com Content Network
Management of ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) focuses on symptoms management, as no treatments that address the root cause of the illness are available. [ 1 ] : 29 Pacing, or regulating one's activities to avoid triggering worse symptoms, is the most common management strategy for post-exertional malaise .
People suffered from "chronic or recurrent fatigue", among a large number of other symptoms. [1]: 28–29 The initial link between elevated antibodies and the Epstein–Barr virus led to the name "chronic Epstein–Barr virus syndrome". The CDC renamed it chronic fatigue syndrome (CFS), as a viral cause could not be confirmed in studies.
Methylphenidate, sold under the brand names Ritalin (/ ˈ r ɪ t ə l ɪ n / RIT-ə-lin) and Concerta (/ k ə n ˈ s ɜːr t ə / kən-SUR-tə) [citation needed] among others, is a central nervous system (CNS) stimulant indicated in the pharmacotherapy of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
The stimulants are the first line of treatment for ADHD, with proven efficacy, but they do fail in up to 20% of cases, even in patients without tic disorders. [4] Current prescribed stimulant medications include: methylphenidate (brand names Ritalin, Metadate, Concerta), dextroamphetamine (Dexedrine), and mixed amphetamine salts . Other ...
Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use. [222] In 1975, pemoline (Cylert) was approved by the U.S. FDA for use in the treatment of ADHD. While an effective agent for managing ...
The drug reached phase 3 clinical trials for treatment of fatigue prior to the discontinuation of its development for this use in January 2024. [32] Aside from the preceding indications, armodafinil is currently under development for the treatment of eating disorders and, as of January 2024, is in phase 3 trials for this use.
Treatment of excessive daytime sleepiness (EDS) relies on identifying and treating the underlying disorder which may cure the person from the EDS. Drugs like modafinil , [ 22 ] armodafinil , [ 23 ] pitolisant [ 24 ] (Wakix), sodium oxybate (Xyrem) oral solution, have been approved as treatment for EDS symptoms in the United States.
Methylphenidate is a much more reliable example of an NDRI (the action that it displays on the DAT usually getting preferential treatment). Methylphenidate is used in the treatment of ADHD; its use in treating depression is not known to have been reported, but it is presumed owing to its psychomotor activating effects and it functioning as a ...